Onkologi 4/2016
Restricted Access
Web-läsaren som du använder har begränsningar som ej garanterar en optimal läsupplevelse.

Du kan fortsätta till publikationen eller änvända en av våra rekommenderade web-läsare:

gå vidare till publikationen
Next
Last
Information om publikationen
Ansvarig utgivare:
publikationens titel:
Onkologi 4/2016
Språk:
Swedish

Antal sidor:
84
Antal länkar i publikaitonen:
57

Privacy policy
When accesing the visulazation tool you agree upon knowing and accepting the terms of use and the privacy policy of the owner of the webpage through which you are accesing the digital publication.
The hybrid format that the viewer is visualizing modifies the size of the publication provided by the responsable of the same in order to make it fit the screen and permit certain functions that increases the usefullness of the original document that it is showing.
The viewer is simply reproducing the content that is the leagal property of the responsable for the publication.
All contents and links that you access through the viewer is under the sole responsability of the owner of the website or the responsable for the publication making the content and the opinions expressed in the same their reponsability exclusively.
WEB ANALYTICS, COOKIES AND SESION CONTROL
This viewer is using web analytics tecnology that makes it possible for us to collect certain technical information like your Internet protocol, IP-adress, your computer's operating system, type of internet browser, your prefered language and country of origin, screen resolution, software version with which you are accessing aswell as the referring page adress when accessing the publication and the links being used while navigating the viewer.
The company which is the owner of the viewer and that is manageing it for its own purposes informs you that the viewer uses Cookies with the purpose of being able to offer you a personalized experience which is smooth and comfortable. When accessing this visualization tool you are informed that in order to control the service quality the above indicated technical data is obtained which in turn permits us to adjust the visualization to the technical requirements of all users and to normalize it periodically.
Also, the viewer controls and treats access data of the viewer, more specifically pages viewed, options and links used.
None of the data handeled and mentioned above involves personal data nor does it permit knowing the identity of the visitors.
DATA CONCERNING ECOLOGICAL FOOTPRINTS
The viewer handles and manages data which permits it to calculate the ecological footprint which is genereated through the use of the same. The system handles data regarding the printed publication in order to know and certify the saving of paper and the and the reduction of the greenhouse effect created by the original printed and distributed version while, at the same time, compensating for printed pages and copies made from the viewer upon request from the user.
None of the treatments of data mentioned above involves personal data nor do they permit knowing the identity of the visitors except for cases in which the user registers in the centralized CSR system and thereby gives the authorization of the specific and irrefutable treatment of data.
PUBLICATION STATISTICS
The viewer also treats statistical data of the publication on behalf of the owner of the same, like the number of visitors and users, with the purpose of producing relevant information for managing his/her printing and comunication policy and also facilitate the access to relevant technical and operational statistics regarding the visitors and users of publications contracted for the viewer.
Hybrid Publication provides general information, technical data, staistics for visitors, actions used and anonymos forms related to the publication to the responsable of the same. However, these general data and statistics do not include personal information except for cases where a service that modifies these conditions is contracted prior to the publication or where these kind of services are provided directly by the responsable without the paticipation of the manager of the viewer.
EXERCISING RIGHTS
You can exercise your rights through contacting the responsable of the publication by following the indications concerning privacy policy in the website from which you have accessed the same.
Hjälp
svep
Bläddra till vänster eller höger
pinch
Zooma in eller Zooma ut på en sida
förflytta
När du zoomat in, förflytta dig runt på sidan
enkel tap
Visa/Dölj menyfält
dubbel tap
På en länk, öppna. Ej på en länk, zooma in eller zooma ut på en sida
rotera
Ändra olika vyer för landskap (2 sidor), porträtt (1 sida)
Innehållsförteckning
I VARJE NUMMER
Redaktörens rader
Redaktionsråd
Notiser
Läkemedelsbehandling
Individualiserad läkemedelsbehandling – här är vi och så kan framtiden se ut
Standardiserade vårdförlopp
Inte omöjligt förändra ”det omöjliga”
Myelom
”Förbättrad behandling av myelom gör MRD-analyser allt viktigare”
Prostatacancer
Var går gränsen för nyttan av radikal lokalbehandling av prostatacancer?
Nya rön om ärftlighet för prostatacancer
Så kan helt nya metoder användas för att diagnostisera aggressiv prostatacancer
Kliniken i fokus
Privata Christinakliniken kombinerar den lilla enhetens fördelar med storsjukhusets resurser
Hematologi
Målinriktade behandlingar i fokus på EHA i Köpenhamn
Ny ordförande i Svenska KLL-gruppen
Utbildning
Kurs i Magnetresonanstomografi
Prostatacancerkurs
Kurs i tumörimmunologi
Stipendium
Kliniska Forskartjänster
Sök i text
Skriv det ord du letar efter i publikationen och klicka på knappen. Sökresultaten kommer att ha en länk som, när du klickar på den, tar dig direkt till den sidan där sökordet finns.

Ekologiskt fotavtryck
NUMMER 4/ 2016
Behandling med Tanlar Mekinist i 1:a linjen
pvisar strre OS effekt n vid behandling med
BRAF inhibitor i monoterapi
Tanlar Mekinist
Tanlar
Tanlar Mekinist
Vemurafenib
74% OS
Berknad
verlevnadsfrekvens
Berknad
verlevnadsfrekvens
vid 1 r
51% OS
vid 1 r
42% OS
vid 2 r
68% OS
Onkologi i Sverige Tidningen fr svensk cancervrd
25 mnader verlevnad i median
vid 2 r
72% OS
51% OS
vid 2 r
65% OS
vid 1 r
38% OS
vid 2 r
Patienter under risk
vid 1 r
Patienter under risk
Page 2Page 3Page 4Page 5Page 6Page 7Page 8Page 9Page 10Page 11Page 12Page 13Page 14Page 15Page 16Page 17Page 18Page 19Page 20Page 21Page 22Page 23Page 24Page 25Page 26Page 27Page 28Page 29Page 30Page 31Page 32Page 33Page 34Page 35Page 36Page 37Page 38Page 39Page 40Page 41Page 42Page 43Page 44Page 45Page 46Page 47Page 48Page 49Page 50Page 51Page 52Page 53Page 54Page 55Page 56Page 57Page 58Page 59Page 60Page 61Page 62Page 63Page 64Page 65Page 66Page 67Page 68Page 69Page 70Page 71Page 72Page 73Page 74Page 75Page 76Page 77Page 78Page 79Page 80Page 81Page 82Page 83Page 84